1s19 › Citations

Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.

Tocchini-Valentini G, Rochel N, Wurtz JM, Moras D
J Med Chem 47 1956-61 (2004)
Cited: 65 times
EuropePMC logo PMID: 15055995

Abstract

The plethora of actions of 1alpha,25(OH)(2)D(3) in various systems suggested wide clinical applications of vitamin D nuclear receptor (VDR) ligands in treatments of inflammation, dermatological indication, osteoporosis, cancers, and autoimmune diseases. More than 3000 vitamin D analogues have been synthesized in order to reduce the calcemic side effects while maintaining the transactivation potency of these ligands. Here, we report the crystal structures of VDR ligand binding domain bound to two vitamin D agonists of therapeutical interest, calcipotriol and seocalcitol, which are characterized by their side chain modifications. These structures show the conservation of the VDR structure and the adaptation of the side chain anchored by hydroxyl moieties. The structure of VDR-calcipotriol helps us to understand the structural basis for for the switching of calcipotriol to a receptor antagonist by further side chain modification. The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.

Articles - 1s19 mentioned but not cited (11)

  1. Variability in docking success rates due to dataset preparation. Corbeil CR, Williams CI, Labute P. J Comput Aided Mol Des 26 775-786 (2012)
  2. BSP-SLIM: a blind low-resolution ligand-protein docking approach using predicted protein structures. Lee HS, Zhang Y. Proteins 80 93-110 (2012)
  3. Improving accuracy and efficiency of blind protein-ligand docking by focusing on predicted binding sites. Ghersi D, Sanchez R. Proteins 74 417-424 (2009)
  4. Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles. Park SJ, Kufareva I, Abagyan R. J Comput Aided Mol Des 24 459-471 (2010)
  5. Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays. Mahapatra D, Franzosa JA, Roell K, Kuenemann MA, Houck KA, Reif DM, Fourches D, Kullman SW. Sci Rep 8 8883 (2018)
  6. High-throughput quantum-mechanics/molecular-mechanics (ONIOM) macromolecular crystallographic refinement with PHENIX/DivCon: the impact of mixed Hamiltonian methods on ligand and protein structure. Borbulevych O, Martin RI, Westerhoff LM. Acta Crystallogr D Struct Biol 74 1063-1077 (2018)
  7. A multidisciplinary approach disclosing unexplored Aflatoxin B1 roles in severe impairment of vitamin D mechanisms of action. Persico M, Sessa R, Cesaro E, Dini I, Costanzo P, Ritieni A, Fattorusso C, Grosso M. Cell Biol Toxicol 39 1275-1295 (2023)
  8. A multilayer dynamic perturbation analysis method for predicting ligand-protein interactions. Gu L, Li B, Ming D. BMC Bioinformatics 23 456 (2022)
  9. A pocket-based 3D molecule generative model fueled by experimental electron density. Wang L, Bai R, Shi X, Zhang W, Cui Y, Wang X, Wang C, Chang H, Zhang Y, Zhou J, Peng W, Zhou W, Huang B. Sci Rep 12 15100 (2022)
  10. Optimal ligand descriptor for pocket recognition based on the Beta-shape. Kim JK, Won CI, Cha J, Lee K, Kim DS. PLoS One 10 e0122787 (2015)
  11. The vitamin D receptor as a potential target for the toxic effects of per- and polyfluoroalkyl substances (PFASs): An in-silico study. Azhagiya Singam ER, Durkin KA, La Merrill MA, Furlow JD, Wang JC, Smith MT. Environ Res 217 114832 (2023)


Reviews citing this publication (15)

  1. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Physiol Rev 96 365-408 (2016)
  2. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Reschly EJ, Krasowski MD. Curr Drug Metab 7 349-365 (2006)
  3. Vitamin D and Its Synthetic Analogs. Maestro MA, Molnár F, Carlberg C. J Med Chem 62 6854-6875 (2019)
  4. Functional evolution of the pregnane X receptor. Iyer M, Reschly EJ, Krasowski MD. Expert Opin Drug Metab Toxicol 2 381-397 (2006)
  5. Vitamin D receptor agonists' anti-inflammatory properties. Vojinovic J. Ann N Y Acad Sci 1317 47-56 (2014)
  6. Vitamin D receptor ligands: the impact of crystal structures. Carlberg C, Molnár F, Mouriño A. Expert Opin Ther Pat 22 417-435 (2012)
  7. The vitamin D receptor. Carlberg C, Seuter S. Dermatol Clin 25 515-23, viii (2007)
  8. Structural considerations of vitamin D signaling. Molnár F. Front Physiol 5 191 (2014)
  9. 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR. Wu B, Li S, Dong D. Drug Discov Today 18 574-581 (2013)
  10. Prevention of chronic allograft rejection by Vitamin D receptor agonists. Adorini L, Amuchastegui S, Daniel KC. Immunol Lett 100 34-41 (2005)
  11. High-resolution crystallography and drug design. Cachau RE, Podjarny AD. J Mol Recognit 18 196-202 (2005)
  12. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment. Ono Y. J Steroid Biochem Mol Biol 139 88-97 (2014)
  13. Steroids: partial synthesis in medicinal chemistry. Hanson JR. Nat Prod Rep 23 100-107 (2006)
  14. Structural refinement of seco-steroidal skeleton and the biological activity through nuclear receptors. Kittaka A. Yakugaku Zasshi 128 1235-1250 (2008)
  15. New Approaches to Assess Mechanisms of Action of Selective Vitamin D Analogues. Pike JW, Meyer MB. Int J Mol Sci 22 12352 (2021)

Articles citing this publication (39)

  1. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A, Welsh J, Byers SW. Mol Cell 21 799-809 (2006)
  2. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. Lou YR, Molnár F, Peräkylä M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C, Tuohimaa P. J Steroid Biochem Mol Biol 118 162-170 (2010)
  3. Functional evolution of the vitamin D and pregnane X receptors. Reschly EJ, Bainy AC, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD. BMC Evol Biol 7 222 (2007)
  4. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR. Structure 18 1332-1341 (2010)
  5. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, Hsieh JC, Haussler CA, Haussler MR. J Cell Biochem 94 917-943 (2005)
  6. Evolution of pharmacologic specificity in the pregnane X receptor. Ekins S, Reschly EJ, Hagey LR, Krasowski MD. BMC Evol Biol 8 103 (2008)
  7. Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Nucl Recept 3 2 (2005)
  8. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. Daniel C, Radeke HH, Sartory NA, Zahn N, Zuegel U, Steinmeyer A, Stein J. J Pharmacol Exp Ther 319 622-631 (2006)
  9. Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. Ciesielski F, Rochel N, Moras D. J Steroid Biochem Mol Biol 103 235-242 (2007)
  10. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A. Mol Pharmacol 67 1566-1573 (2005)
  11. Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket. Molnár F, Peräkylä M, Carlberg C. J Biol Chem 281 10516-10526 (2006)
  12. Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A, Wietrzyk J. Oncol Rep 32 491-504 (2014)
  13. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Tavera-Mendoza LE, Quach TD, Dabbas B, Hudon J, Liao X, Palijan A, Gleason JL, White JH. Proc Natl Acad Sci U S A 105 8250-8255 (2008)
  14. The retinoid X receptor ligand restores defective signalling by the vitamin D receptor. Sánchez-Martínez R, Castillo AI, Steinmeyer A, Aranda A. EMBO Rep 7 1030-1034 (2006)
  15. Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. Masuno H, Ikura T, Morizono D, Orita I, Yamada S, Shimizu M, Ito N. J Lipid Res 54 2206-2213 (2013)
  16. Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Gocek E, Kiełbiński M, Wyłób P, Kutner A, Marcinkowska E. Steroids 73 1359-1366 (2008)
  17. Realizing private and practical pharmacological collaboration. Hie B, Cho H, Berger B. Science 362 347-350 (2018)
  18. Identification of a highly potent vitamin D receptor antagonist: (25S)-26-adamantyl-25-hydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-epi-vitamin D3 (ADMI3). Igarashi M, Yoshimoto N, Yamamoto K, Shimizu M, Ishizawa M, Makishima M, DeLuca HF, Yamada S. Arch Biochem Biophys 460 240-253 (2007)
  19. Structure-based design of a superagonist ligand for the vitamin D nuclear receptor. Hourai S, Rodrigues LC, Antony P, Reina-San-Martin B, Ciesielski F, Magnier BC, Schoonjans K, Mouriño A, Rochel N, Moras D. Chem Biol 15 383-392 (2008)
  20. 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure. Shimizu M, Miyamoto Y, Takaku H, Matsuo M, Nakabayashi M, Masuno H, Udagawa N, DeLuca HF, Ikura T, Ito N. Bioorg Med Chem 16 6949-6964 (2008)
  21. New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. Mizwicki MT, Bula CM, Bishop JE, Norman AW. J Steroid Biochem Mol Biol 103 243-262 (2007)
  22. The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. Zella LA, Chang CY, McDonnell DP, Pike JW. Arch Biochem Biophys 460 206-212 (2007)
  23. 22-ene-25-oxa-vitamin D: a new vitamin D analogue with profound immunosuppressive capacities. Daniel C, Schlauch T, Zügel U, Steinmeyer A, Radeke HH, Steinhilber D, Stein J. Eur J Clin Invest 35 343-349 (2005)
  24. Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. Rochel N, Hourai S, Pérez-García X, Rumbo A, Mourino A, Moras D. Arch Biochem Biophys 460 172-176 (2007)
  25. On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist. Mizwicki MT, Bula CM, Mahinthichaichan P, Henry HL, Ishizuka S, Norman AW. J Biol Chem 284 36292-36301 (2009)
  26. 2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism. Yoshimoto N, Inaba Y, Yamada S, Makishima M, Shimizu M, Yamamoto K. Bioorg Med Chem 16 457-473 (2008)
  27. New derivatives of 1alpha,25-dihydroxy-19-norvitamin D3 with two substituents at C-2: synthesis and biological activity. Shimizu M, Iwasaki Y, Shimazaki M, Amano Y, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem Lett 15 1451-1455 (2005)
  28. Analogs of 1alpha,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs. Shimazaki M, Miyamoto Y, Yamamoto K, Yamada S, Takami M, Shinki T, Udagawa N, Shimizu M. Bioorg Med Chem 14 4645-4656 (2006)
  29. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain. Shimizu M, Miyamoto Y, Kobayashi E, Shimazaki M, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem 14 4277-4294 (2006)
  30. Structure-activity relationship studies on vitamin D lactam derivatives as vitamin D receptor antagonist. Cho K, Uneuchi F, Kato-Nakamura Y, Namekawa J, Ishizuka S, Takenouchi K, Nagasawa K. Bioorg Med Chem Lett 18 4287-4290 (2008)
  31. The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung. Ormerod AK, Xing Z, Pedigo NG, Mishra A, Kaetzel DM. Exp Lung Res 34 155-182 (2008)
  32. Isolation and identification of 2alpha,25-dihydroxyvitamin D3, a new metabolite from Pseudonocardia autotrophica 100U-19 cells incubated with Vitamin D3. Takeda K, Kominato K, Sugita A, Iwasaki Y, Shimazaki M, Shimizu M. Steroids 71 736-744 (2006)
  33. Design, synthesis, evaluation, and structure of vitamin D analogues with furan side chains. Fraga R, Zacconi F, Sussman F, Ordóñez-Morán P, Muñoz A, Huet T, Molnár F, Moras D, Rochel N, Maestro M, Mouriño A. Chemistry 18 603-612 (2012)
  34. Synthesis and biological activity of two pregnane derivatives with a triazole or imidazole ring at C-21. Silva-Ortiz AV, Bratoeff E, Ramírez-Apan MT, García-Becerra R, Ordaz-Rosado D, Noyola-Martínez N, Castillo-Bocanegra R, Barrera D. J Steroid Biochem Mol Biol 159 8-18 (2016)
  35. Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications. Kaya T, Swamy N, Persons KS, Ray S, Mohr SC, Ray R. Bioorg Chem 37 57-63 (2009)
  36. A human vitamin D receptor mutant activated by cholecalciferol. Ousley AM, Castillo HS, Duraj-Thatte A, Doyle DF, Azizi B. J Steroid Biochem Mol Biol 125 202-210 (2011)
  37. Efficient stable isotope labeling and purification of vitamin D receptor from inclusion bodies. Zhu J, Rao H, Tonelli M, Westler WM, Singarapu KK, Markley JL, DeLuca HF, Assadi-Porter FM. Protein Expr Purif 85 25-31 (2012)
  38. Rapid Rescoring and Refinement of Ligand-Receptor Complexes Using Replica Exchange Molecular Dynamics with a Monte Carlo Pose Reservoir. Alcantara J, Chiu K, Bickel JD, Rizzo RC, Simmerling C. J Chem Theory Comput 19 7934-7945 (2023)
  39. Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D3 Derivatives with Structure-Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs. Maekawa K, Ishizawa M, Ikawa T, Sajiki H, Matsumoto T, Tokiwa H, Makishima M, Yamada S. Biomolecules 13 1082 (2023)


Quick links